Literature DB >> 16723578

Functional, biophysical, and structural bases for antibacterial activity of tigecycline.

Matthew W Olson1, Alexey Ruzin, Eric Feyfant, Thomas S Rush, John O'Connell, Patricia A Bradford.   

Abstract

Tigecycline is a novel glycylcycline antibiotic that possesses broad-spectrum activity against many clinically relevant species of bacterial pathogens. The mechanism of action of tigecycline was delineated using functional, biophysical, and molecular modeling experiments in this study. Functional assays showed that tigecycline specifically inhibits bacterial protein synthesis with potency 3- and 20-fold greater than that of minocycline and tetracycline, respectively. Biophysical analyses demonstrated that isolated ribosomes bind tigecycline, minocycline, and tetracycline with dissociation constant values of 10(-8), 10(-7), and >10(-6) M, respectively. A molecular model of tigecycline bound to the ribosome was generated with the aid of a 3.40-angstrom resolution X-ray diffraction structure of the 30S ribosomal subunit from Thermus thermophilus. This model places tigecycline in the A site of the 30S subunit and involves substantial interactions with residues of H34 of the ribosomal subunit. These interactions were not observed in a model of tetracycline binding. Modeling data were consistent with the biochemical and biophysical data generated in this and other recent studies and suggested that tigecycline binds to bacterial ribosomes in a novel way that allows it to overcome tetracycline resistance due to ribosomal protection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723578      PMCID: PMC1479133          DOI: 10.1128/AAC.01499-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3.

Authors:  M Pioletti; F Schlünzen; J Harms; R Zarivach; M Glühmann; H Avila; A Bashan; H Bartels; T Auerbach; C Jacobi; T Hartsch; A Yonath; F Franceschi
Journal:  EMBO J       Date:  2001-04-17       Impact factor: 11.598

2.  In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.

Authors:  H W Boucher; C B Wennersten; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

3.  The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit.

Authors:  D E Brodersen; W M Clemons; A P Carter; R J Morgan-Warren; B T Wimberly; V Ramakrishnan
Journal:  Cell       Date:  2000-12-22       Impact factor: 41.582

4.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA.

Authors:  J Wang; P Morin; W Wang; P A Kollman
Journal:  J Am Chem Soc       Date:  2001-06-06       Impact factor: 15.419

5.  Identification of a ribosomal ATPase in Escherichia coli cells.

Authors:  M C Kiel; H Aoki; M C Ganoza
Journal:  Biochimie       Date:  1999-12       Impact factor: 4.079

6.  Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis.

Authors:  T M Murphy; J M Deitz; P J Petersen; S M Mikels; W J Weiss
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

7.  Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

Authors:  Charles R Dean; Melissa A Visalli; Steven J Projan; Phaik-Eng Sum; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

Review 8.  New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors.

Authors:  Ian Chopra
Journal:  Drug Resist Updat       Date:  2002 Jul-Aug       Impact factor: 18.500

9.  In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.

Authors:  Peter J Petersen; Patricia A Bradford; William J Weiss; Timothy M Murphy; P E Sum; Steven J Projan
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis.

Authors:  Melissa A Visalli; Ellen Murphy; Steven J Projan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

View more
  63 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  Structural characterization of an alternative mode of tigecycline binding to the bacterial ribosome.

Authors:  Andreas Schedlbauer; Tatsuya Kaminishi; Borja Ochoa-Lizarralde; Neha Dhimole; Shu Zhou; Jorge P López-Alonso; Sean R Connell; Paola Fucini
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

3.  Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains.

Authors:  A Doléans-Jordheim; E Bergeron; F Bereyziat; S Ben-Larbi; O Dumitrescu; M-A Mazoyer; F Morfin; C Dumontet; J Freney; L P Jordheim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-15       Impact factor: 3.267

Review 4.  Ribosome-targeting antibiotics and mechanisms of bacterial resistance.

Authors:  Daniel N Wilson
Journal:  Nat Rev Microbiol       Date:  2014-01       Impact factor: 60.633

5.  Cryo-EM structure of the tetracycline resistance protein TetM in complex with a translating ribosome at 3.9-Å resolution.

Authors:  Stefan Arenz; Fabian Nguyen; Roland Beckmann; Daniel N Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

6.  Rampant Parasexuality Evolves in a Hospital Pathogen during Antibiotic Selection.

Authors:  Kathryn Beabout; Troy G Hammerstrom; Tim T Wang; Minny Bhatty; Peter J Christie; Gerda Saxer; Yousif Shamoo
Journal:  Mol Biol Evol       Date:  2015-06-09       Impact factor: 16.240

7.  The innate growth bistability and fitness landscapes of antibiotic-resistant bacteria.

Authors:  J Barrett Deris; Minsu Kim; Zhongge Zhang; Hiroyuki Okano; Rutger Hermsen; Alexander Groisman; Terence Hwa
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

8.  Mechanism of action of the novel aminomethylcycline antibiotic omadacycline.

Authors:  Michael P Draper; S Weir; A Macone; J Donatelli; C A Trieber; S K Tanaka; Stuart B Levy
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

Review 9.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

10.  Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.

Authors:  Cristina Tanaseanu; Slobodan Milutinovic; Petre I Calistru; Janos Strausz; Marius Zolubas; Valeriy Chernyak; Nathalie Dartois; Nathalie Castaing; Hassan Gandjini; C Angel Cooper
Journal:  BMC Pulm Med       Date:  2009-09-09       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.